The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
The composition of the gut microbiome can control innate and adaptive immunity and has emerged as a key regulator of tumor growth, especially in the context of immune checkpoint blockade (ICB) therapy. However, the underlying mechanisms for how the microbiome affects tumor growth remain unclear. Pancreatic ductal adenocarcinoma (PDAC) tends to be refractory to therapy, including ICB. Using a nontargeted, liquid chromatography–tandem mass spectrometry–based metabolomic screen, we identified the gut microbe–derived metabolite trimethylamine N -oxide (TMAO), which enhanced antitumor immunity to PDAC. Delivery of TMAO intraperitoneally or via a dietary choline supplement to orthotopic PDAC-bearing mice reduced tumor growth, associated with an immunostimulatory tumor-associated macrophage (TAM) phenotype, and activated effector T cell response in the tumor microenvironment. Mechanistically, TMAO potentiated the type I interferon (IFN) pathway and conferred antitumor effects in a type I IFN–dependent manner. Delivering TMAO-primed macrophages intravenously produced similar antitumor effects. Combining TMAO with ICB (anti-PD1 and/or anti-Tim3) in a mouse model of PDAC significantly reduced tumor burden and improved survival beyond TMAO or ICB alone. Last, the levels of bacteria containing CutC (an enzyme that generates trimethylamine, the TMAO precursor) correlated with long-term survival in patients with PDAC and improved response to anti-PD1 in patients with melanoma. Together, our study identifies the gut microbial metabolite TMAO as a driver of antitumor immunity and lays the groundwork for potential therapeutic strategies targeting TMAO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, in several cohorts of patients with melanoma, the clinical response to anti-PD-1 antibodies correlated with the expression of the CUTC gene170 in the faecal microbiome40,91,128.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [170]
In the citing paper
“However, this effect appears to be context-dependent, as preclinical studies in breast159 and pancreatic cancer models160 indicate that TMAO may improve responses to ICIs (Fig. 3a).”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [160]
In the citing paper
“For instance, TMAO and its microbial precursors reprogrammed tumor-associated macrophages toward a pro-inflammatory, type I interferon (IFN)-dependent phenotype, augmenting CD8+ T-cell activity and potentiating anti-PD-1 efficacy in murine pancreatic cancer.160”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [160]
In the citing paper
“In an orthotopic PDAC mouse model, TMAO rendered tumours responsive to anti-PD-1 and anti-TIM3 antibodies170.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 2×
“M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.”
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302 · cited 2×
“Reads were aligned against a collection of CutC reference protein sequences that was downloaded through NCBI Reference Sequence Database bacterial (RefSeq), using BlastX (60) with E value < 1 × 10−7.”
MethodFast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · cited 1×
“RNA-seq data were aligned using the bowtie2 (49) algorithm against hg19 human or mm10 mouse genome version, and the RSEM v1.”
MethodCytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179 · cited 1×
“12 software (50) was used to estimate read counts and RPKM (reads per kilobase, per million mapped reads) values using gene information from human Ensembl transcriptome version GRCh37.”
MethodIntegrated analysis of multimodal single-cell data
Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W. M., Zheng, S., Butler, A., Lee, M. J., Wilk, A. J., Darby, C., Zagar, M., et al. (2020) · doi:10.1101/2020.10.12.335331 · Cited by 15,508 · cited 1×
“Cell clustering, marker identification, and visualization were performed using Seurat v4 (55).”
MethodThe Perseus computational platform for comprehensive analysis of (prote)omics data
Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., & Cox, J. (2016) · Nature Methods · doi:10.1038/nmeth.3901 · Cited by 8,803
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Cited by
Items 101–200 of 341
Léon-Letelier, R. A., Dou, R., Vykoukal, J. V., Yip-Schneider, M., Maitra, A., Irajizad, E., Wu, R., Dennison, J. B., Do, K., Zhang, J., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad186 · Cited by 24
The gut microbiome modulate response to immunotherapy in cancer
Jiang, S., Kang, Z., Chen, Y., & Fang, J. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2634-7 · Cited by 22
“The intratumoral microbiota has the capacity to instruct TAMs through the TLR signaling pathway, leading to immune tolerance, and instigating an immunosuppressive atmosphere within PDAC (Pushalkar et al., 2018).”
InfluentialGut Microbiota-Derived Metabolites and Cardiovascular Disease: Focus on Trimethylamine- N -oxide
He, M., Tan, C. P., & Liu, Y. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c08378 · Cited by 21
Mirji, G., Bhat, S. A., Sayed, M. E. E., Reiser, S. K., Gavara, S. P., Ye, Y., Miyamoto, T., Zhang, W., Vogel, P., Cassel, J. A., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116749 · Cited by 18
“3,9 The uremic toxin p-cresyl sulfate promotes atherogenesis in murine models and is associated with vascular inflammation in hemodialysis patients, while unconjugated p-cresol enhances low-density lipoprotein (LDL) uptake via increased macropinocytosis in macrophages.”
Self-citationFecal Microbiota Transplantation as a Cancer Therapeutic
Stoff, R., Wolf, Y., & Boursi, B. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000651 · Cited by 23
Immuno-oncology-microbiome axis of gastrointestinal malignancy
Lin, Q., Guan, S.-W., & Yu, H. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i5.757 · Cited by 28
Xu, J., Kang, Y., Zhong, Y., Ye, W., Sheng, T., Wang, Q., Zheng, J., Yang, Q., Yi, P., & Li, Z. (2023) · Cancer Medicine · doi:10.1002/cam4.6283 · Cited by 19
Zhou, Z., Zheng, J., Lu, Y., Mai, Z., Lin, Y., Lin, P., Zheng, Y., Chen, X., Xu, R., Zhao, X., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00575-7 · Cited by 20
“In addition, metabolic support via exogenous metabolites can help remodel the TME to be more supportive of immune activity [69, 70].”
BackgroundCholine in immunity: a key regulator of immune cell activation and function
Maia, C., Fung, C. W., & Sánchez‐López, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1617077 · Cited by 20
Intratumoral microbiota remodeling of the tumor microenvironment impact solid tumor immunotherapy
Jia, J., Gao, W., Wang, C., Liu, L., Li, Y., Sun, Z., Yang, C., Chen, Y., Yu, H., & Cheng, Y. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08211-w · Cited by 21
“Recent research has indicated that the intratumoral microbiota (or its metabolites) may improve the effectiveness of PDAC immunotherapy [28, 30, 56, 69, 102 – 105] (Fig.”
InfluentialPro-Inflammatory Food, Gut Microbiota, and Cardiovascular and Pancreatic Diseases
Chen, B., Patel, S., Bao, L., Nadeem, D., & Krittanawong, C. (2024) · Biomolecules · doi:10.3390/biom14020210 · Cited by 23
Kırsoy, F., Yalnız, M., Bahçecioğlu, İ. H., Artaş, H., Türkoğlu, S., Solmaz, O., & Tawheed, A. (2024) · Internal and Emergency Medicine · doi:10.1007/s11739-024-03685-6 · Cited by 18
Impact of gut microbiome in the development and treatment of pancreatic cancer: Newer insights
Bangolo, A., Trivedi, C. P., Jani, I., Pender, S., Khalid, H., Alqinai, B., Intisar, A., Randhawa, K., Moore, J., Deugd, N. D., et al. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i25.3984 · Cited by 17
GMMAD: a comprehensive database of human gut microbial metabolite associations with diseases
Wang, C., Kuang, X., Wang, Q.-Q., Zhang, G., Cheng, Z., Deng, Z., & Guo, F.-B. (2023) · BMC Genomics · doi:10.1186/s12864-023-09599-5 · Cited by 17
“Recently, some studies also reported that TMAO might be a key activator of antitumor immunity [8, 9].”
BackgroundLi, D., Lan, X., Xu, L., Zhou, S., Luo, H., Zhang, X., Yu, W., Yang, Y., & Fang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1552010 · Cited by 20
Guo, Y., Xiao, Y., Zhang, C., Wang, Y., Cao, G., Tse, K. Y., Han, Z., Li, F., & Zhi, Y. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1574511 · Cited by 17
Wang, S., Ni, Y., Zhou, S., Peng, H., Cao, Y., Zhu, Y., Gong, J., Lu, Q., Han, Z., Lin, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1591151 · Cited by 19
Microbial metabolites in tumor epigenetic regulation
Zhang, W., Zhang, H., Liao, Y., Jiang, S., Zhang, H., Huang, C., Song, Z., Zhao, R., Lü, P., Kang, X., et al. (2026) · iMeta · doi:10.1002/imt2.70115 · Cited by 19
Qian, J., Zhang, X., Wei, B., Tang, Z., & Zhang, B. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188943 · Cited by 17
Research progress of diabetic retinopathy and gut microecology
Wang, R., Wang, Q., Bai, Y., Bi, Y.-G., & Cai, S.-J. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1256878 · Cited by 17
Chandra, S., & Vassar, R. J. (2024) · Immunological Reviews · doi:10.1111/imr.13412 · Cited by 18
Training the microbiota to increase immune checkpoint blockade and to reduce toxicity
Rescigno, M. (2023) · European Journal of Immunology · doi:10.1002/eji.202250183 · Cited by 15
“This was associated with the shaping of the tumor microenvironment, in particular immunostimulatory tumor-associated macrophage, and with an activated effector T-cell response [39].”
BackgroundShen, J., Ye, X., Hou, H. Y., & Wang, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112243 · Cited by 18
Merali, N., Chouari, T. A. M., Sweeney, C., Halle-Smith, J. M., Jessel, M.-D., Wang, B., Brien, J. O., Suyama, S., Jiménez, J. I., Roberts, K. J., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001762 · Cited by 16
“Employing an orthotopic mouse model of PDAC, one study has demonstrated that TMAO relieves immunosuppression in the PDAC TME [109] .”
BackgroundResultInflammation, microbiota, and pancreatic cancer
Chen, X., Sun, F., Wang, X., Feng, X., Aref, A. R., Tian, Y., Ashrafizadeh, M., & Wu, D. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03673-6 · Cited by 16
“…tumor growth in mouse models Induction of immunostimulatory TAM phenotype Stimulation of T cell responses Enhancing the IFN pathway causing anti-cancer impacts in a type I IFN-dependent manner [215] Tumor microbiome (enriched in anaerobic Bacteroidales and microaerophilic Campylobac-terales) The”
Zhou, Z., Lv, Y., Zuo, A., Zhu, X., Xu, Y., Zuo, L., Xu, H., Liu, S., Zhang, Y., Weng, S., et al. (2025) · hLife · doi:10.1016/j.hlife.2025.05.008 · Cited by 16
“In pancreatic cancer mouse models, the microbial metabolite trimethylamine N-oxide (TMAO) synergizes with immune checkpoint blockade by reprogramming tumor-associated macrophages (TAMs) and dendritic cells (DCs) toward immunostimulatory phenotypes, thereby boosting anti-tumor immunity [14].”
Intestinal microbiota: A bridge between intermittent fasting and tumors
Liu, J., Shao, N., Qiu, H., Zhao, J., Chen, C., Wan, J., He, Z., Zhao, X., & Xu, L. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115484 · Cited by 17
Zheng, S., Li, K.-Z., Feng, G., Wang, Y.-T., Jia-ning, W. A. N. G., Li, S., & Sun, Y.-D. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02513-5 · Cited by 17
“Furthermore, TMAO exposure markedly increased PD-1 and Tim-3 levels on CD8 + T cells, making PDAC tumors more responsive to blockade of PD-1 or Tim-3 immune checkpoints [55].”
Role of Gut Microbiome in Oncogenesis and Oncotherapies
Peddireddi, R. S. S., Kuchana, S. K., Kode, R., Khammammettu, S., Koppanatham, A., Mattigiri, S., Gobburi, H., & Alahari, S. K. (2025) · Cancers · doi:10.3390/cancers18010099 · Cited by 15
“As PDAC is notoriously therapy-resistant, microbiome signatures may guide biomarker discovery and novel therapeutic approaches [67,68].”
Pratelli, G., Tamburini, B., Carlisi, D., Blasio, A. D., D’Anneo, A., Emanuele, S., Notaro, A., Affranchi, F., Giuliano, M., Seidita, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914619 · Cited by 16
High-throughput metabolomics identifies new biomarkers for cervical cancer
Li, X., Zhang, L.-Y., Huang, X., Peng, Q., Zhang, S., Tang, J., Wang, J., Gui, D., & Zeng, F. (2024) · Discover Oncology · doi:10.1007/s12672-024-00948-8 · Cited by 16
“…identified the microbiome-derived metabolite TMAO drived immune activation and boosted responses to immune checkpoint blockade in pancreatic cancer [42], TMAO or its precursor choline, may represent a novel therapeutic strategy to promote the efficacy of immunotherapy in triple-negative breast…”
BackgroundSidiropoulos, T. A., Dovrolis, N., Katifelis, H., Michalopoulos, N. V., Kokoropoulos, P., Arkadopoulos, N. F., & Gazouli, M. (2024) · Biomedicines · doi:10.3390/biomedicines12051040 · Cited by 15
Shaikh, F. Y., Lee, S., White, J. R., Zhao, Y., Ferri, J. T., Pereira, G., Landon, B. V., Ke, S., Hu, C., Feliciano, J. L., et al. (2024) · Cancers · doi:10.3390/cancers16213644 · Cited by 17
Zhu, S., Wang, Y., Li, Y., Li, N., Zheng, Y., Li, Q., Guo, H., Sun, J., Zhai, Q., & Wang, Q. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1499591 · Cited by 14
Shi, C., Chen, L., Pi, H., Cui, H., Fan, C., Tan, F., Qu, X., Sun, R., Zhao, F., Song, Y., et al. (2023) · Oncogenesis · doi:10.1038/s41389-023-00500-3 · Cited by 17
“However, the gut microbiome also has a profound effect on immune checkpoint blockade [37 – 39].”
BackgroundMicrobiome modulation of antigen presentation in tolerance and inflammation
He, Y., Mohapatra, G., Asokan, S., Nobs, S. P., & Elinav, E. (2024) · Current Opinion in Immunology · doi:10.1016/j.coi.2024.102471 · Cited by 13
Zhang, Y., & Liu, Z. (2025) · Advanced Science · doi:10.1002/advs.202508692 · Cited by 18
Wu, S., Wen, S., An, K., Xiong, L., Zeng, H., Niu, Y., & Yin, T. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1281451 · Cited by 15
“According to research by Rahul et al., the gut microbial-derived metabolite trimethylamine N-oxide (TMAO) enhanced the efficacy of PC by directly driving in macrophages the immunostimulatory phenotype and enhanced the response of PC to immune checkpoint blockade (Mirji et al., 2022).”
MethodThe role of microbiota in tumorigenesis, progression and treatment of bladder cancer
Peng, Z., Zhuang, J., & Shen, B. (2023) · Microbiome Research Reports · doi:10.20517/mrr.2023.47 · Cited by 15
Tumour‐associated neutrophils: Potential therapeutic targets in pancreatic cancer immunotherapy
Wu, Q., Mao, H., Jiang, Z., & Tang, D. (2024) · Immunology · doi:10.1111/imm.13765 · Cited by 13
“…N1 phenotype and has been integrated into ICI therapy for PC. Studies have revealed that trimethylamine N-oxide (TMAO), a microbial gut metabolite, improves the type-I IFN pathway, thereby increasing the efficacy of check-point immunotherapy and improving the survival of tumour-bearing mice [139].”
BackgroundXu, Y., Le, J., Qin, J., Zhang, Y., Yang, J., Chen, Z., Li, C., Xiang, Q., & Zhang, A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107364 · Cited by 13
TMAO metaorganismal pathway and chronic inflammatory diseases
Wang, Z., Man, S., & Koeth, R. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001339 · Cited by 14
The gut-tumor connection: the role of microbiota in cancer progression and treatment strategies
Wei, Z., Gao, G., He, Q., Kwok, L. Y., & Sun, Z. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.038 · Cited by 14
Gut microbiome, a novel precision medicine biomarker for hepatocellular carcinoma
Chen, P., Devkota, S., Shiao, S. L., Hendifar, A. E., & Yang, J. D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1568962 · Cited by 13
Stonans, I., Kuzmina, J., Poļaka, I., Grīnberga, S., Sevostjanovs, E., Liepinsh, E., Aleksandraviča, I., Šantare, D., Kiršners, A., Škapars, R., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13071341 · Cited by 13
“While some studies in mice models demonstrate a TMAO immunostimulatory effect, improved response to immune checkpoint inhibitors [47] and some protective effects on cellular proteins under stress conditions [48], TMAO is mainly associated with elevated cardiometabolic risks.”
BackgroundMicrobes in the tumor microenvironment: New additions to break the tumor immunotherapy dilemma
Zhou, L., Fan, S., Zhang, W., Wang, D., & Tang, D. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127777 · Cited by 12
Metagenomic Microbial Signatures for Noninvasive Detection of Pancreatic Cancer
Chen, Y., Nian, F., Chen, J., Jiang, Q., Yuan, T., Feng, H., Shen, X., & Dong, L. (2025) · Biomedicines · doi:10.3390/biomedicines13041000 · Cited by 15
“A recent study suggested that TMAO could drive antitumor immunity by inducing the immunostimulatory phenotype of macrophages and enhancing the function of effector T cells [18].”
Yang, H. K., Cao, B., Tang, J., & Wang, J. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1592549 · Cited by 13
Mechanistic Development of Cancers Associated with Processed Meat Products: A Review
Bedale, W. A., Milkowski, A. L., Czuprynski, C. J., & Richards, M. P. (2023) · Meat and Muscle Biology · doi:10.22175/mmb.15762 · Cited by 11
Ren, Y., Wang, Z., Li, Y., Zhou, J., Huang, H., Chang, S., Wu, Y., & Xue, J. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae082 · Cited by 13
Microbial molecules, metabolites, and malignancy
Thomas, R. M. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101128 · Cited by 11
Decoding immunometabolism with next-generation tools: lessons from dendritic cells and T cells
Wang, Y., Wang, L., & Ho, P. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00569-z · Cited by 13
“LC-MS/MS-based metabolomic screening identi fi ed the gut microbe – derived metabolite trimethylamine N-oxide (TMAO) as an enhancer of IFN signaling pathways, promoting an immunostimulatory phenotype in tumor-associated macrophages (TAMs) and stimulating effector T cell responses (Mirji et al, 2022).”
Communication between gut microbiota-derived metabolites and the tumor microenvironment
Hu, X., Li, B., Li, Y., Liang, Y., & Huang, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1649438 · Cited by 11
Microbial metabolites for cancer immunotherapy: Current evidence and future directions
Wang, X., Liang, J.-J., Duan, X., & Chen, G. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.10.005 · Cited by 12
Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
Huang, Y., Chau, Y. F., Bai, H., Wu, X., & Duan, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914521 · Cited by 12
Yang, Q., Cai, Y., Guo, S., Wang, Z., Wang, Y., Yu, X., Sun, W., Qiu, S., & Zhang, A. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1238822 · Cited by 10
Zarour, H. M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.010 · Cited by 10
Wang, M., Huang, Y., Xin, M., Li, T., Wang, X., Fang, Y., Liang, S., Cai, T., Xu, X., Dong, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1156471 · Cited by 13
“Immunotherapy cannot ameliorate clinical outcomes in PDAC patients due to the highly immunosuppressive tumor microenvironment.”
BackgroundInfluentialGao, X., & Jiang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1359029 · Cited by 12
Song, J., Li, J., Zhang, A., Tan, X., Li, S., Luo, L., Wang, S., Wei, G., Zhang, Z., & Huo, J.-G. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136390 · Cited by 11
Fang, Q., Lei, Y., Wu, H., Li, C., Jiang, J., Wang, S., Wu, Y., Chen, L., Ouyang, D., Li, X., et al. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120223 · Cited by 9
Unraveling the Role of the Microbiota in Cancer Immunotherapy: A New Frontier
Wang, S., Li, S., Zhang, M., Liu, R., Ye, X., Mao, S., Yu, J., Xie, X., & Tan, W. (2025) · Research · doi:10.34133/research.0744 · Cited by 13
Sun, S., Wang, L., Cui, K., Ding, Y., Wei, Y., Zheng, Y., Shen, Z., Zhu, L., Yang, Y., Pu, Y., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011831 · Cited by 9
“In some flow cytometry analyses, the cell count per sample ranged from 500 to 1,000, which may affect analytical precision.”
Microbial metabolites in tumor metabolic reprogramming and immunotherapy: new insights
Wang, Y., Huang, D., Wang, R., Yin, J.-J., Pei, J., & Zhang, C. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1706040 · Cited by 10
Wang, S., Ma, G., Qi, C., Cheng, S., Lai, H., Zhou, L., Wu, G., Chen, Z., Mao, X., Jing, T., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.11.052 · Cited by 12
Harnessing the Microbiome in Cancer Immunotherapy: Regulation, Prediction, and Therapeutic Targeting
Zarour, H. M., & Trinchieri, G. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082323-114522 · Cited by 15
Vilbert, M., Koch, E. C., Rose, A. A. N., Laister, R. C., Gray, D., Sotov, V., Penny, S. L., Spreafico, A., Hogg, D., Pinto, D. M., et al. (2023) · Cancers · doi:10.3390/cancers15143708 · Cited by 10
“Similarly, serum levels of the metabolite trimethylamine N-oxide (TMAO) impacted macrophage phenotype, T cell activation, and response to ICI therapy in a murine pancreatic tumor model [9].”
BackgroundLimeta, A., Gatto, F., Herrgård, M. J., Ji, B., & Nielsen, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.07.032 · Cited by 9
“short-chain fatty acids [65,66], TMAO [67] and bile acids [68]), direct induction of”
BackgroundGao, W., Wang, X., Shi, Y., Wu, G., Zhou, M., & Lin, X. (2024) · Genes and Immunity · doi:10.1038/s41435-024-00306-2 · Cited by 9
“One study has shown that a microbe-derived metabolite, trimethylamine oxide, can drive the activation of anti-tumor immunity, enhancing the therapeutic response of pancreatic cancer to immune checkpoint blocking therapy [11].”
RetractedZhang, Z., Xiong, Q., Xu, Y., Cai, X., Zhang, L., & Zhu, Q. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041398 · Cited by 12
“Previous trials have suggested that the gut microbiota can metabolize trimethylamine N-oxide (TMAO) to increase the number of antitumor TICs in PC, such as CD8+ T cells [45].”
BackgroundThe Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer
Rogers, S. C., Charles, A. M., & Thomas, R. M. (2023) · Cancers · doi:10.3390/cancers15245708 · Cited by 11
“Mirji [30] ICI Enhanced immune activation and PDAC xenograft response to ICI with the microbial metabolite trimethylamine N-oxide.”
BackgroundYuan, R., Li, Y., Wang, Y., Li, Q., Guo, C., & Wang, L. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00809-4 · Cited by 8
“The host genome and microbiome jointly produce a wide range of metabolites that act as critical signalling molecules and energy substrates, in fl uencing the immune system beyond the intestinal mucosal barrier 40,41 .”
Yan, Y., Li, J., Xu, H., Yang, C., Li, G., Feng, Y., Wang, Q., Li, L., Wu, R., Sun, H., et al. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118996 · Cited by 8
Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Mimpen, I. L., Battaglia, T., Parra-Martinez, M., Toner-Bartelds, C., Zeverijn, L. J., Geurts, B. S., Verkerk, K., Hoes, L. R., van Renterghem, A. W. J., Noë, M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1669 · Cited by 11
Microbiota and cancer immunotherapy: Mechanisms, clinical implications, and precision therapeutics
Wei, D., Sun, Y., Han, J., & Liu, J. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.12.002 · Cited by 9
Gut microbiota drives cancer evolution and therapy resistance
Min, S., Zhang, Y., Zhang, H., & Liu, Q. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02564-8 · Cited by 10
“…one study revealed that TMAO reprograms macrophages in a type I interferon-dependent manner, thereby converting the immunosuppressive tumor microenvironment of pancreatic cancer into an immuno-logically active state, which enhances T-cell function and improves the efficacy of ICB [103].”
Self-citationLiao, J., Zhou, Z., Lv, Y., Zhang, Y., Liu, S., Tang, H., Qv, F., Wang, S., Yang, L., Lu, Y., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1667180 · Cited by 9
Self-citationMicrobiota-derived metabolites as modulators of cancer immunotherapy response
Toner-Bartelds, C., Mimpen, I. L., Parra-Martinez, M., Burgering, B. M. T., & Voest, E. E. (2026) · Nature Communications · doi:10.1038/s41467-026-72178-1 · Cited by 10
“A well-characterised example of this is TMAO.”
InfluentialPouliquen, D. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1403037 · Cited by 8
Anticarcinogenic effects of ursodeoxycholic acid in pancreatic adenocarcinoma cell models
Kovács, P., Schwarcz, S., Nyerges, P., Bíró, T. I., Ujlaki, G., Bai, P., & Mikó, E. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1487685 · Cited by 8
Qiu, Y.-F., Ye, J., Xie, J.-J., Mao, X., Liu, Y.-L., Fang, Q., Qian, Y., Zou, W., Yu, C., & Liao, Z. (2024) · Molecular Genetics and Genomics · doi:10.1007/s00438-024-02125-6 · Cited by 10
Wang, F., Fan, J., Pan, W., Liu, M., Wang, J., Wei, X., Xian, Y., Chen, S., Cui, C., Chen, Y., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.10.012 · Cited by 14
Lucia, S. S. D., Nista, E. C., Candelli, M., Archilei, S., Deutschbein, F., Capuano, E., Gasbarrini, A., Franceschi, F., & Pignataro, G. (2025) · Cancers · doi:10.3390/cancers17223618 · Cited by 7
“By activating the type I interferon (IFN) pathway, TMAO exerts anti-inflammatory effects and has been linked to improved survival in pancreatic cancer patients [34].”
Liu, Y., Zhang, H.-Y., Hong, X.-Y., Wu, Y., Li, M., & Zheng, H. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111862 · Cited by 8
Azılı, C., Tamam, S., Benk, M. Ş., Deryol, R., Çulcu, S., & Ünal, A. E. (2023) · Medicine · doi:10.1097/md.0000000000035069 · Cited by 8
“Hepatic dysfunction can indicate a patient’s prognosis for several pathologies.[16,37,44] Table 4”
BackgroundInfluentialTop advances of the year: Pancreatic cancer
Warren, E. A. K., Lesinski, G. B., & Maithel, S. K. (2023) · Cancer · doi:10.1002/cncr.35031 · Cited by 8
“38 In the other study, obese mice were found to be resistant to chemotherapy, driven by an enrichment of gut bacteria producing queuo-sine, which upregulates the expression of antioxidant protein PRDX1.”
BackgroundMicrobiota mechanisms in cancer progression and therapy
Zhang, X., Fam, K. T., Dai, T., & Hang, H. C. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.04.005 · Cited by 9
Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy
Hu, J., Feng, T., Zhang, L., Zhou, Q., & Zhu, L. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003687 · Cited by 8
“[12] TMAO acts by enhancing the activation of the type I IFN pathway, and its antitumor benefits are realized in a manner that is contingent upon type I IFN.”
InfluentialMultifaceted effects of the microbiome in pancreatic cancer: from association to modulation
Thomas, R. M. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01119-y · Cited by 6
“As discussed previously, Mirji and colleagues demonstrated that the microbial metabolite, TMAO, was able to facilitate immune activation in the PDAC TME 103 .”
Strategic modulation of the gastrointestinal microbiome to enhance pancreatic cancer immunotherapy
Jagwani, S., Musumeci, L., Flores, L., Mackenzie, G. G., & Amiji, M. M. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104528 · Cited by 6
Targeting Microbe-Mediated Macrophage Education: A Novel Paradigm in Cancer Immunotherapy
Xu, R., Zhao, X., Chen, X., Zhou, H., & Cui, L. (2025) · Biomaterials Research · doi:10.34133/bmr.0294 · Cited by 6
“This shift in macrophage polarization synergizes with immune checkpoint blockade, providing a potential therapeutic avenue for enhancing cancer immunotherapy [ 57 ].”
Unveiling the interplay between microbiota and PD1/PD-L1 axis in tumor immunity and immunotherapy
Lu, Q., Wu, J., Yu, X., Qian, J., & Song, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690374 · Cited by 6
Gao, J., Zhang, J., & Tang, L. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110399 · Cited by 6
The Intestinal Microbiota and Therapeutic Responses to Immunotherapy
Herrera, P. S., & van den Brink, M. R. M. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062722-035210 · Cited by 6
Halle-Smith, J. M., Pearce, H., Nicol, S. M., Hall, L. A., Powell-Brett, S. F., Beggs, A. D., Iqbal, T. H., Moss, P. A. H., & Roberts, K. J. (2024) · Cancers · doi:10.3390/cancers16050996 · Cited by 9
“Encouragingly, technology now exists that allows specific beneficial bacteria strains to be cultured and administered using so-called next-generation probiotics [108].”
BackgroundSepulveda, M., Rasic, M., Lei, Y. M., Kwan, M., Chen, L., Chen, Y., Perkins, D. L., & Alegre, M. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.03.020 · Cited by 6
Wu, B., Quan, C., He, Y., Matsika, J., Huang, J., Liu, B., & Chen, J. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2371543 · Cited by 7
“This suggests that strategies to alter TMAO levels may be a promising therapeutic approach for managing PDAC [63].”
Recent advances in the role of high-salt diet in anti- and pro-cancer progression
Tang, S., Xu, J., Wan, P., Jin, S., Zhang, Y., Xun, L., Wang, J., Luo, M., Chen, W., Zuo, Z., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1542157 · Cited by 8
Self-citationUnlocking the Microbial Symphony: The Interplay of Human Microbiota in Cancer Immunotherapy Response
Chacon, J. A., Faizuddin, F., McKee, J. C., Sheikh, A., Vasquez, V. M., Gadad, S. S., Mayer, G., Siby, S., McCabe, M. M., & Dhandayuthapani, S. (2025) · Cancers · doi:10.3390/cancers17050813 · Cited by 8
“A healthy, symbiotic microbiome supports the activation and persistence of TILs by fostering a pro-inflammatory environment conducive to anti-tumor immunity [107].”
Stieg, D. C., Parris, J. L. D., Yang, T. H. L., Mirji, G., Reiser, S. K., Murali, N., Werts, M., Barnoud, T., Lu, D. Y., Shinde, R. S., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0149 · Cited by 6
“Bone marrow–derived macrophages (BMDM) were generated by culturing bone marrow cells from P47 and S47 mice with MCSF (BioLegend; 576406), as described previously (33).”
MethodSelf-citation
Metadata
- Authors
- Mirji, G., Worth, A., Bhat, S. A., El Sayed, M., Kannan, T., Goldman, A. R., Tang, H.-Y., Liu, Q., Auslander, N., Dang, C. V., Abdel-Mohsen, M., Kossenkov, A., Stanger, B. Z., & Shinde, R. S.
- Affiliations
- The Wistar Institute (US)
- Immunology, Microenvironment and Metastasis Program, the Wistar Institute, Philadelphia, PA, USA.
- University of Pennsylvania (US)
- Corresponding author
- Shinde, Rahul S.
- ORCID
- Venue
- Science Immunology
- Published
- 2022-09-30
- Volume
- 7
- Issue
- 75
- Pages
- eabn0704-eabn0704
- ISSN
- 2470-9468 (ISSN-L)
- PMC
- PMC9925043
- OpenAlex
- W4295519447
- Cited by
- 327
- References
- 62
- Citations by year
- 2026: 83 · 2025: 91 · 2024: 89 · 2023: 62 · 2022: 2
- FWCI
- 26.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (1s10od023586-01)
- National Cancer Institute (R01CA057341, R21CA259240, R50CA221838, R50CA211199, R01CA252225, P30CA010815)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- trimethylamine N-oxide, gut microbiota, pancreatic ductal adenocarcinoma, immune checkpoint blockade, antitumor immunity, tumor-associated macrophages, type I interferon pathway, choline, CutC, anti-PD-1, effector T cells, tumor microenvironment, melanoma
- MeSH terms
- Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Animals, Methylamines, Pancreatic Neoplasms, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.